6. SHARE-BASED COMPENSATION	6 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	NOTE 6 SHARE-BASED COMPENSATION 2021 Equity Incentive Plan In February 2021, shareholders of the Company approved the 2021 Equity Incentive Plan (the “2021 Plan”), which is administered by the Compensation Committee of the Board of Directors and authorizes 1,291,000 shares of common stock for grants of various types of equity awards to officers, directors, employees and consultants. Upon approval of the 2021 Plan, no additional awards were granted under the 2011 Long Term Incentive Plan (the “2011 Plan”), which expired according to its terms in March 2021. Shares authorized under the 2021 Plan include 1,000,000 new shares and 291,000 shares that remained available under the 2011 Plan. Awards which are forfeited or expire are eligible for regrant under the 2021 Plan. The exercise prices of stock options granted may not be less than the fair market value of the common stock as quoted on the Nasdaq stock market on the grant date and the expiration date of option awards may not exceed 10 years. Stock Options No options were granted during the three or six months ended March 31, 2021. In February 2020, the Company granted options to non-employee directors to purchase an aggregate of 248,000 shares of its common stock at an exercise price of $1.13 per shares. The options vested one year from the date of grant, expire five years from the date of grant and had an aggregate grant date fair value of $145,000, which was recognized ratably over the vesting period. These options, which were the only options granted during the three and six months ended March 31, 2020, had a grant-date fair value of $0.58 per share. During the six months ended March 31, 2021, the Company issued 69,000 shares of its common stock pursuant to the exercise of stock options for aggregate cash proceeds of $144,000. There were no options exercised during the six months ended March 31, 2020. The Company recognized compensation expense for stock option awards of $21,000 and $36,000 during the three months ended March 31, 2021 and 2020, respectively, and $63,000 and $69,000 during the six months ended March 31, 2021 and 2020, respectively, in its condensed consolidated statements of operations. At March 31, 2021, there was $10,000 of total unrecognized compensation cost related to nonvested stock option awards that is expected to be recognized over a weighted average period of 1.0 year.

6. SHARE-BASED COMPENSATION

6 Months Ended

Mar. 31, 2021

Share-based Payment Arrangement [Abstract]

NOTE 6 SHARE-BASED COMPENSATION

2021 Equity Incentive Plan

In February 2021, shareholders of the Company approved the 2021 Equity Incentive Plan (the “2021 Plan”), which is administered by the Compensation Committee of the Board of Directors and authorizes 1,291,000 shares of common stock for grants of various types of equity awards to officers, directors, employees and consultants. Upon approval of the 2021 Plan, no additional awards were granted under the 2011 Long Term Incentive Plan (the “2011 Plan”), which expired according to its terms in March 2021. Shares authorized under the 2021 Plan include 1,000,000 new shares and 291,000 shares that remained available under the 2011 Plan. Awards which are forfeited or expire are eligible for regrant under the 2021 Plan. The exercise prices of stock options granted may not be less than the fair market value of the common stock as quoted on the Nasdaq stock market on the grant date and the expiration date of option awards may not exceed 10 years.

Stock Options

No options were granted during the three or six months ended March 31, 2021.

In February 2020, the Company granted options to non-employee directors to purchase an aggregate of 248,000 shares of its common stock at an exercise price of $1.13 per shares. The options vested one year from the date of grant, expire five years from the date of grant and had an aggregate grant date fair value of $145,000, which was recognized ratably over the vesting period. These options, which were the only options granted during the three and six months ended March 31, 2020, had a grant-date fair value of $0.58 per share.

During the six months ended March 31, 2021, the Company issued 69,000 shares of its common stock pursuant to the exercise of stock options for aggregate cash proceeds of $144,000. There were no options exercised during the six months ended March 31, 2020.

The Company recognized compensation expense for stock option awards of $21,000 and $36,000 during the three months ended March 31, 2021 and 2020, respectively, and $63,000 and $69,000 during the six months ended March 31, 2021 and 2020, respectively, in its condensed consolidated statements of operations.

At March 31, 2021, there was $10,000 of total unrecognized compensation cost related to nonvested stock option awards that is expected to be recognized over a weighted average period of 1.0 year.